Corpus Intelligence IC Memo — ASCENSION ST. VINCENT FISHERS 2026-04-26 07:45 UTC
IC Memo — ASCENSION ST. VINCENT FISHERS
Investment Committee Memorandum | IN | 46 beds | Grade C | EBITDA uplift $5.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ASCENSION ST. VINCENT FISHERS

CCN 150181 | HAMILTON, IN | 46 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ASCENSION ST. VINCENT FISHERS is a 46-bed suburban community hospital in HAMILTON, IN with $75.7M in net patient revenue and a 19.8% operating margin. The hospital serves a payer mix of 20.1% Medicare, 4.0% Medicaid, and 75.8% commercial.

Thesis: Turnaround. Our ML models identify $5.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 19.8% to 27.2% (+736bps).

Net Revenue HCRIS$75.7M
Current EBITDA COMPUTED$15.0M
Operating Margin COMPUTED19.8%
Occupancy HCRIS20.7%
Revenue / Bed COMPUTED$1.6M
Net-to-Gross HCRIS30.2%
Distress Probability ML53.8%

2. Market Context & Competitive Position

171
IN Hospitals
-1.1%
State Median Margin
89
Comparable Hospitals

IN has 171 Medicare-certified hospitals with a median operating margin of -1.1%. The target's margin of 19.8% places it above the state median. Among 89 size-comparable peers (23-92 beds), the median margin is -1.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (23-92), prioritizing same-state peers. 89 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ASCENSION ST. VINCENT FISHERS (Target)IN46$75.7M19.8%
INDIANA ORTHOPAEDIC HOSPITAL LIN38$196.8M31.2%
LAPORTE HOSPITALIN74$192.4M19.3%
SCHNECK MEDICAL CENTERIN60$184.2M-0.8%
ORTHOPAEDIC HOSPT.AT PARKVIEWIN37$175.7M36.8%
LUTHERAN MUSCULOSKELETAL CENTEIN39$168.9M25.0%
WITHAM MEMORIAL HOSPITALIN50$158.5M-11.6%
FRANCISCAN HEALTH MOORESVILLEIN80$157.3M26.2%
MAJOR HOSPITALIN46$156.9M-9.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $5.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.6M+210bp18mo
Cost to Collect4.5%2.5%$1.5M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$921K+122bp9mo
Clean Claim Rate88.0%96.0%$48K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.6M
Cost to Collect
$1.5M
Denial Rate Reduction
$1.5M
A/R Days Reduction
$921K
Clean Claim Rate
$48K
Total EBITDA Uplift$5.6M
Current EBITDA$15.0M
+ RCM Uplift+$5.6M
Pro Forma EBITDA$20.6M
Current Margin19.8%
Pro Forma Margin27.2%
WC Released (1x)$2.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$23.1M$154.8M6.70x46.3%
Base (11x exit)10.0x11.0x$23.1M$177.8M7.69x50.4%
Bull Case9.0x11.0x$20.8M$203.7M9.79x57.8%
Bull (12x exit)9.0x12.0x$20.8M$228.4M10.98x61.5%
Bear Case11.0x10.0x$25.4M$119.5M4.70x36.3%
Bear (11x exit)11.0x11.0x$25.4M$139.7M5.49x40.6%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 20.7%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 53.8% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 89 hospitals with 23-92 beds
  • Same-state prioritization (n=90)
  • Comp margins: P25=-11.9% / P50=-1.8% / P75=8.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.